Lupus Nephritis Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

February 14 23:26 2023
Lupus Nephritis Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Lupus Nephritis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Lupus Nephritis therapeutics market is anticipated to grow in the coming years owing to the increasing prevalent population of Lupus Nephritis in the 7MM and the launch of emerging therapies.

Talking about the emerging treatment horizon of Lupus Nephritis, several companies, including Roche, Novartis, AstraZeneca, and others, are eyeing the existing untapped market of Lupus Nephritis and trying their best to grab a significant market share. Some of the emerging therapies by these key players have already demonstrated positive late-stage results among Lupus Nephritis-affected individuals and are in further clinical evaluation.

Lupus Nephritis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Lupus Nephritis Market. 

The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Lupus Nephritis Pipeline Analysis

Lupus Nephritis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Lupus Nephritis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Lupus Nephritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

DelveInsight’s Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Molecule Type


Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Small molecule


Mechanism of Action of the Emerging Pipeline Therapies

  • CD6 antigen inhibitors

  • Agammaglobulinaemia tyrosine kinase inhibitors

  • CD40 ligand inhibitors

  • Antibody-dependent cell cytotoxicity

  • Interleukin-23 subunit p19 inhibitors

  • LANCL2 agonist

  • Interferon alpha inhibitors

  • IL17A protein inhibitors

  • Extracellular trap inhibitors


Learn How the Ongoing Clinical & Commercial Activities will Affect the Lupus Nephritis Therapeutic Segment @

Lupus Nephritis Therapeutics Landscape

There are approx. 20+ key companies developing therapies for Lupus Nephritis. Currently, BeiGene is leading the therapeutics market with its Lupus Nephritis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Lupus Nephritis Therapeutics Market Include:

  • Novartis Pharmaceuticals

  • Hoffmann-La Roche

  • Janssen Research & Development

  • BeiGene

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

  • Alexion Pharmaceuticals

  • Omeros Corporation

  • Corestem, Inc.

  • Bristol-Myers Squibb

  • Boehringer Ingelheim

  • Apellis Pharmaceuticals

  • AstraZeneca

  • Kezar Life Sciences

  • Equillium

  • Eledon Pharmaceuticals

  • Resolve Therapeutics

And Many Others

Lupus Nephritis Drugs Covered in the Report Include:

  • Zanubrutinib: BeiGene

  • Ravulizumab: Alexion Pharmaceuticals

  • Anifrolumab: AstraZeneca

  • Itolizumab: Equillium

  • Secukinumab: Novartis Pharmaceuticals

  • NTR-441: Neutrolis Therapeutics

  • AT-1501: Eledon Pharmaceuticals

  • Zanubrutinib: BeiGene

  • Obinutuzumab: Roche

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Lupus Nephritis Current Treatment Patterns

4. Lupus Nephritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Lupus Nephritis Late Stage Products (Phase-III)

7. Lupus Nephritis Mid-Stage Products (Phase-II)

8. Lupus Nephritis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Lupus Nephritis Discontinued Products

13. Lupus Nephritis Product Profiles

14. Key Companies in the Lupus Nephritis Market

15. Key Products in the Lupus Nephritis Therapeutics Segment

16. Dormant and Discontinued Products

17. Lupus Nephritis Unmet Needs

18. Lupus Nephritis Future Perspectives

19. Lupus Nephritis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Other Trending Healthcare Reports By DelveInsight

Lupus Nephritis Market Outlook

Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States